Praxis Precision Medicines, Inc. (PRAX) has a negative trailing P/E of -23.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 35.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.22%, forward earnings yield 2.82%. PEG 0.24 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -1.4 | 0.00 | 2.46 | 0.00 | - |
| 2019 | -1.2 | -0.09 | 1.06 | 0.00 | - |
| 2020 | -8.0 | 0.11 | 1.71 | 0.00 | - |
| 2021 | -5.0 | 0.12 | 3.33 | 0.00 | - |
| 2022 | -0.5 | -0.03 | 1.44 | 0.00 | - |
| 2023 | -1.2 | 0.02 | 2.11 | 60.04 | - |
| 2024 | -7.5 | 0.17 | 3.09 | 161.13 | - |
| 2025 | -21.9 | -0.68 | 7.55 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-306.73 | $0.00 | $-26.54M | - |
| 2019 | $-348.24 | $0.00 | $-35.51M | - |
| 2020 | $-103.61 | $0.00 | $-61.82M | - |
| 2021 | $-58.96 | $0.00 | $-166.88M | - |
| 2022 | $-69.33 | $0.00 | $-213.07M | - |
| 2023 | $-18.69 | $2.45M | $-123.28M | -5037.9% |
| 2024 | $-10.21 | $8.55M | $-182.82M | -2137.5% |
| 2025 | $-13.48 | $0.00 | $-303.27M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-15.07 | $-22.19 – $-13.04 | $6.38M | $1.15M – $25M | 12 |
| 2027 | $-9.59 | $-14.95 – $-5.17 | $298.82M | $110.27M – $418.5M | 11 |
| 2028 | $9.61 | $-8.88 – $31.39 | $1.09B | $1.09B – $1.09B | 13 |
| 2029 | $33.90 | $5.97 – $74.06 | $2.19B | $801.91M – $4.19B | 11 |
| 2030 | $59.55 | $10.48 – $130.09 | $3.46B | $1.27B – $6.61B | 5 |
